There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioxcel Therapeutics (BTAI – Research Report), Spruce Biosciences (SPRB – Research Report) and Alpha Tau Medical Ltd (DRTS – Research Report) with bullish sentiments.
Bioxcel Therapeutics (BTAI)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Bioxcel Therapeutics, with a price target of $11.00. The company’s shares closed last Thursday at $4.38, close to its 52-week low of $3.82.
According to TipRanks.com, Selvaraju ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Bioxcel Therapeutics is a Moderate Buy with an average price target of $14.17, which is a 241.4% upside from current levels. In a report issued on August 15, Truist Financial also maintained a Buy rating on the stock with a $31.00 price target.
See the top stocks recommended by analysts >>
Spruce Biosciences (SPRB)
H.C. Wainwright analyst Boobalan Pachaiyappan reiterated a Buy rating on Spruce Biosciences today and set a price target of $10.00. The company’s shares closed last Thursday at $2.33.
According to TipRanks.com, Pachaiyappan is a 1-star analyst with an average return of
Spruce Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $8.50, which is a 281.2% upside from current levels. In a report issued on August 14, RBC Capital also maintained a Buy rating on the stock with a $8.00 price target.
Alpha Tau Medical Ltd (DRTS)
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Alpha Tau Medical Ltd, with a price target of $9.00. The company’s shares closed last Thursday at $3.60, close to its 52-week low of $2.75.
According to TipRanks.com, Chen has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Alpha Tau Medical Ltd has an analyst consensus of Strong Buy, with a price target consensus of $11.33.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BTAI:
- Biotech Alert: Searches spiking for these stocks today
- Largest borrow rate increases among liquid names
- Redfin upgraded, CSSE downgraded: Wall Street’s top analyst calls
- BioXcel Therapeutics price target lowered to $20 from $75 at Canaccord
- BioXcel Therapeutics price target lowered to $31 from $71 at Truist
